BMS-488043
Code | Size | Price |
---|
TAR-T30527-1mg | 1mg | £181.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T30527-5mg | 5mg | £344.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T30527-10mg | 10mg | £480.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T30527-25mg | 25mg | £736.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T30527-50mg | 50mg | £994.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T30527-100mg | 100mg | £1,315.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T30527-500mg | 500mg | £2,456.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
BMS-488043 is a novel and unique oral small molecule inhibitor that inhibits the attachment of human immunodeficiency virus type 1 (HIV-1) to CD4(+) lymphocytes.
CAS:
452296-83-2
Formula:
C22H22N4O5
Molecular Weight:
422.441
Pathway:
Microbiology/Virology|Proteases/Proteasome
Purity:
0.98
SMILES:
COc1cnc(OC)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12
Target:
HIV Protease
References
1. Habgood M, Sugden IJ, Kazantsev AV, Adjiman CS, Pantelides CC. Efficient Handling of Molecular Flexibility in Ab Initio Generation of Crystal Structures. J Chem Theory Comput. 2015 Apr 14;11(4):1957-69. doi: 10.1021/ct500621v. PubMed PMID: 26574397.
2. Patel RV, Park SW. Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase. Bioorg Med Chem. 2015 Sep 1;23(17):5247-63. doi: 10.1016/j.bmc.2015.06.016. Epub 2015 Jun 14. Review. PubMed PMID: 26116177.
3. Sato S, Inokuma T, Otsubo N, Burton DR, Barbas CF 3rd. Chemically Programmed Antibodies AS HIV-1 Attachment Inhibitors. ACS Med Chem Lett. 2013 May 9;4(5):460-465. PubMed PMID: 23750312; PubMed Central PMCID: PMC3673733.
4. Regueiro-Ren A, Xue QM, Swidorski JJ, et al. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]py ridin-3-yl)ethane-1,2-dione (BMS-585248). J Med Chem. 2013 Feb 28;56(4):1656-69. doi: 10.1021/jm3016377. Epub 2013 Feb 7. PubMed PMID: 23360431.